Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucia Festino

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Expert Review of Clinical Pharmacology|September 1, 2018
Selecting immuno-oncology-based drug combinations - what should we be considering?Lucia Festino, Vito Vanella, Claudia Trojaniello, et al.
Expert Review of Clinical Pharmacology|January 18, 2019
Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutationsClaudia Trojaniello, Lucia Festino, Vito Vanella, et al.
Expert Opinion on Emerging Drugs|March 9, 2021
Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanomaVito Vanella, Lucia Festino, Maria Grazia Vitale, et al.
Current Medicinal Chemistry|December 6, 2019
Melanoma: Prognostic Factors and Factors Predictive of Response to TherapyMartina Strudel, Lucia Festino, Vito Vanella, et al.
American Journal of Clinical Dermatology|May 25, 2017
MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid TumorsAntonio M Grimaldi, Ester Simeone, Lucia Festino, et al.
Discovery Medicine|July 16, 2015
Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathwayAntonio Maria Grimaldi, Ester Simeone, Lucia Festino, et al.
Expert Opinion on Therapeutic Targets|March 1, 2012
Therapy innovation for the treatment of pancreatic neuroendocrine tumorsFerdinando Riccardi, Mimma Rizzo, Lucia Festino, et al.
Oncoimmunology|January 4, 2018
PD-L1 inhibitors in the pipeline: Promise and progressVito Vanella, Lucia Festino, Martina Strudel, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 7, 2017
Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of CareEster Simeone, Antonio M Grimaldi, Lucia Festino, et al.
The Lancet. Oncology|October 5, 2015
PD-L1 expression as a potential predictive biomarkerAlberto Fusi, Lucia Festino, Gerado Botti, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Expert Review of Clinical Pharmacology|September 1, 2018
Selecting immuno-oncology-based drug combinations - what should we be considering?Lucia Festino, Vito Vanella, Claudia Trojaniello, et al.
Expert Review of Clinical Pharmacology|January 18, 2019
Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutationsClaudia Trojaniello, Lucia Festino, Vito Vanella, et al.
Expert Opinion on Emerging Drugs|March 9, 2021
Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanomaVito Vanella, Lucia Festino, Maria Grazia Vitale, et al.
Current Medicinal Chemistry|December 6, 2019
Melanoma: Prognostic Factors and Factors Predictive of Response to TherapyMartina Strudel, Lucia Festino, Vito Vanella, et al.
American Journal of Clinical Dermatology|May 25, 2017
MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid TumorsAntonio M Grimaldi, Ester Simeone, Lucia Festino, et al.
Discovery Medicine|July 16, 2015
Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathwayAntonio Maria Grimaldi, Ester Simeone, Lucia Festino, et al.
Expert Opinion on Therapeutic Targets|March 1, 2012
Therapy innovation for the treatment of pancreatic neuroendocrine tumorsFerdinando Riccardi, Mimma Rizzo, Lucia Festino, et al.
Oncoimmunology|January 4, 2018
PD-L1 inhibitors in the pipeline: Promise and progressVito Vanella, Lucia Festino, Martina Strudel, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 7, 2017
Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of CareEster Simeone, Antonio M Grimaldi, Lucia Festino, et al.
The Lancet. Oncology|October 5, 2015
PD-L1 expression as a potential predictive biomarkerAlberto Fusi, Lucia Festino, Gerado Botti, et al.
Pageof 5